Turning Point Therapeutics, Inc.

NasdaqGS:TPTX 株式レポート

時価総額:US$3.8b

Turning Point Therapeutics 将来の成長

Future 基準チェック /26

Turning Point Therapeuticsは、24.7%と73.9%でそれぞれ年率24.7%で利益と収益が成長すると予測される一方、EPSはgrowで27.8%年率。

主要情報

24.7%

収益成長率

27.8%

EPS成長率

Biotechs 収益成長28.4%
収益成長率73.9%
将来の株主資本利益率n/a
アナリストカバレッジ

Good

最終更新日n/a

今後の成長に関する最新情報

Recent updates

Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report

Jul 21

We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth

Mar 23
We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth

Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth

Dec 06
Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth

The Take On Turning Point Therapeutics

Dec 03

Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts

Aug 15
Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts

Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business

Aug 04
Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business

Turning Point Therapeutics gets FDA orphan drug status for TPX-0022 in gastric cancer

Jun 17

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 08
Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?

Feb 26
Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?

Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study

Jan 29

Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher

Jan 22
Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher

We're Not Worried About Turning Point Therapeutics' (NASDAQ:TPTX) Cash Burn

Jan 13
We're Not Worried About Turning Point Therapeutics' (NASDAQ:TPTX) Cash Burn

Turning Point Therapeutics: An Emerging Growth Story In TKI-Resistant Cancers

Dec 28

Is Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Trading At A 48% Discount?

Dec 15
Is Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Trading At A 48% Discount?

Turning Point Therapeutics' lead candidate nabs accelerated review for lung cancer

Dec 08

Turning Point Therapeutics EPS beats by $0.12, beats on revenue

Nov 12

業績と収益の成長予測

NasdaqGS:TPTX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/2024178-368-304-3587
12/31/202340-449-307-3409
12/31/202211-392-271-2937
6/30/20221-342-263-259N/A
3/31/20226-275-199-197N/A
12/31/202131-237-156-154N/A
9/30/202131-205-136-133N/A
6/30/202155-157-91-90N/A
3/31/202150-132-72-71N/A
12/31/202025-157-84-83N/A
9/30/202025-131-65-63N/A
6/30/2020N/A-134-84-82N/A
3/31/2020N/A-119-78-75N/A
12/31/2019N/A-72-59-58N/A
9/30/2019N/A-60-53-52N/A
6/30/2019N/A-46-40-40N/A
3/31/2019N/A-34-29-28N/A
12/31/2018N/A-25-24-24N/A

アナリストによる今後の成長予測

収入対貯蓄率: TPTX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: TPTX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: TPTX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: TPTXの収益 ( 73.9% ) US市場 ( 9% ) よりも速いペースで成長すると予測されています。

高い収益成長: TPTXの収益 ( 73.9% ) 20%よりも速いペースで成長すると予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: TPTXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘